Increased Postprandial Response of Glucagon-like Peptide-2 in Patients with Chronic Pancreatitis and Pancreatic Exocrine Insufficiency
Overview
Gastroenterology
Affiliations
Background/aims: Glucagon-like peptide-2 (GLP-2) is a nutrient-released gastrointestinal (GI) hormone that acts as an intestinal growth factor, and exogenous GLP-2 has been shown to increase superior mesenteric artery (SMA) blood flow. We aimed to investigate how assimilation of nutrients affects postprandial GLP-2 responses and to correlate these with postprandial SMA blood flow.
Methods: Responses of the GI hormone glucose-dependent insulinotropic polypeptide (GIP) and GLP-2 were measured following an 80-min liquid meal test in 8 patients (6 males) with chronic pancreatitis (CP) and pancreatic exocrine insufficiency (PEI) and 8 healthy control subjects (5 males). Postprandial GI hormone responses were correlated with change in SMA flow as assessed by the resistance index.
Results: Patients with CP and PEI exhibited the greatest postprandial GLP-2 responses (1,870 +/- 249 vs. 1,199 +/- 108 pM.80 min, p = 0.027). No difference was observed with regard to GIP. GLP-2, but not GIP, responses correlated significantly with postprandial SMA flow.
Conclusion: These results suggest that delayed assimilation of nutrients in patients with CP and PEI increases the secretion of GLP-2 - possibly due to delivery of a larger nutrient load to the distal part of the small intestine, where GLP-2 secreting L-cells are abundant - and that this hypersecretion of GLP-2 is associated with a higher SMA flow.
Plasma glucagon-like peptide-2 in cats with chronic enteropathies.
Jugan M, Plattner B, Ford A, Freilich L, Bieberly Z, Schermerhorn T J Feline Med Surg. 2025; 27(1):1098612X241305923.
PMID: 39840661 PMC: 11755514. DOI: 10.1177/1098612X241305923.
Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management.
Goodarzi M, Petrov M Drugs. 2023; 83(12):1077-1090.
PMID: 37410209 PMC: 10361873. DOI: 10.1007/s40265-023-01913-5.
Islet cell dysfunction in patients with chronic pancreatitis.
Roy A, Sahoo J, Kamalanathan S, Naik D, Mohan P, Pottakkat B World J Diabetes. 2020; 11(7):280-292.
PMID: 32843931 PMC: 7415230. DOI: 10.4239/wjd.v11.i7.280.
Hart P, Andersen D, Mather K, Castonguay A, Bajaj M, Bellin M Pancreas. 2018; 47(10):1239-1243.
PMID: 30325863 PMC: 6195331. DOI: 10.1097/MPA.0000000000001168.
Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.
Hart P, Bellin M, Andersen D, Bradley D, Cruz-Monserrate Z, Forsmark C Lancet Gastroenterol Hepatol. 2017; 1(3):226-237.
PMID: 28404095 PMC: 5495015. DOI: 10.1016/S2468-1253(16)30106-6.